Shanghai, China

Shaocong Mo

This inventor holds 1 USPTO granted patent. Top assignee: Fudan University. Active years: 2026.


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Shaocong Mo in Immune-Related Disease Classification

Introduction

Shaocong Mo is an accomplished inventor based in Shanghai, China. He has made significant contributions to the field of molecular typing and subtyping classifiers for immune-related diseases. His innovative approach aims to enhance the understanding and treatment of these complex conditions.

Latest Patents

Shaocong Mo holds a patent for a method and system of molecular typing and subtyping classifier for immune-related diseases. This patent outlines a comprehensive method that includes conducting molecular typing through a clustering algorithm, performing enrichment analysis on marker genes, and evaluating immune cell infiltration. The process ultimately leads to the classification of subtypes and the construction of a support vector machine model to determine the appropriate subtype class for immune-related disease data. He has 1 patent to his name.

Career Highlights

Shaocong Mo is affiliated with Fudan University, where he continues to advance research in the field of immunology. His work is pivotal in developing methodologies that can potentially improve treatment responses for patients with immune-related diseases.

Collaborations

He collaborates with notable colleagues such as Jie Liu and Feifei Luo, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Shaocong Mo's contributions to the field of molecular typing for immune-related diseases exemplify the impact of innovative research on healthcare. His work not only enhances scientific understanding but also paves the way for improved treatment strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…